These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
578 related articles for article (PubMed ID: 20472288)
1. Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma. Jagannath S; Dimopoulos MA; Lonial S Leuk Res; 2010 Sep; 34(9):1111-8. PubMed ID: 20472288 [TBL] [Abstract][Full Text] [Related]
2. Bortezomib: a valuable new antineoplastic strategy in multiple myeloma. Bladé J; Cibeira MT; Rosiñol L Acta Oncol; 2005; 44(5):440-8. PubMed ID: 16118077 [TBL] [Abstract][Full Text] [Related]
3. New drugs for myeloma. Richardson PG; Mitsiades C; Schlossman R; Munshi N; Anderson K Oncologist; 2007 Jun; 12(6):664-89. PubMed ID: 17602058 [TBL] [Abstract][Full Text] [Related]
4. Proteasome inhibition and multiple myeloma. Kanagasabaphy P; Morgan GJ; Davies FE Curr Opin Investig Drugs; 2007 Jun; 8(6):447-51. PubMed ID: 17621873 [TBL] [Abstract][Full Text] [Related]
5. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. Ludwig H; Khayat D; Giaccone G; Facon T Cancer; 2005 Nov; 104(9):1794-807. PubMed ID: 16178003 [TBL] [Abstract][Full Text] [Related]
7. Bortezomib in multiple myeloma. Mateos MV; San Miguel JF Best Pract Res Clin Haematol; 2007 Dec; 20(4):701-15. PubMed ID: 18070714 [TBL] [Abstract][Full Text] [Related]
8. Role of carfilzomib in the treatment of multiple myeloma. Khan RZ; Badros A Expert Rev Hematol; 2012 Aug; 5(4):361-72. PubMed ID: 22992230 [TBL] [Abstract][Full Text] [Related]
9. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Pei XY; Dai Y; Grant S Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093 [TBL] [Abstract][Full Text] [Related]
10. Optimizing the efficacy and safety of bortezomib in relapsed multiple myeloma. Richardson P; Jagannath S; Colson K Clin Adv Hematol Oncol; 2006 May; 4(5):1; discussion 8; suppl 13. PubMed ID: 16830422 [TBL] [Abstract][Full Text] [Related]
11. Synergistic interaction of proteasome and topoisomerase II inhibition in multiple myeloma. von Metzler I; Heider U; Mieth M; Lamottke B; Kaiser M; Jakob C; Sezer O Exp Cell Res; 2009 Aug; 315(14):2471-8. PubMed ID: 19410573 [TBL] [Abstract][Full Text] [Related]
12. Proteasome inhibition for treatment of multiple myeloma: clinical update. Stadtmauer EA J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S10-5. PubMed ID: 19795531 [TBL] [Abstract][Full Text] [Related]
13. Current status of new drugs for the treatment of patients with multiple myeloma. Kenealy M; Prince HM Intern Med J; 2006 Dec; 36(12):781-9. PubMed ID: 17096741 [TBL] [Abstract][Full Text] [Related]
15. Proteasome inhibition: a new approach for the treatment of malignancies. Spano JP; Bay JO; Blay JY; Rixe O Bull Cancer; 2005 Nov; 92(11):E61-6, 945-52. PubMed ID: 16316823 [TBL] [Abstract][Full Text] [Related]
16. Novel agents for relapsed and/or refractory multiple myeloma. Thomas SK; Richards TA; Weber DM Cancer J; 2009; 15(6):485-93. PubMed ID: 20010168 [TBL] [Abstract][Full Text] [Related]
19. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma. Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386 [TBL] [Abstract][Full Text] [Related]
20. Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma. Laubach JP; Schlossman RL; Mitsiades CS; Anderson KC; Richardson PG Expert Rev Hematol; 2011 Feb; 4(1):51-60. PubMed ID: 21322778 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]